Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate (Homo sapiens)

Quality Tags

Ontology Terms

Saving...

Bibliography

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.; ''An integrated genomic analysis of human glioblastoma multiforme.''; PubMed Europe PMC Scholia
2. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.; ''Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.''; PubMed Europe PMC Scholia

History

External references

DataNodes

Name	Type	Database reference	Comment
2HG	Metabolite	CHEBI:32796 (ChEBI)
2OG	Metabolite	CHEBI:30915 (ChEBI)
H+	Metabolite	CHEBI:15378 (ChEBI)
IDH1 R132C mutant	Protein	O75874 (Uniprot-TrEMBL)
IDH1 R132H mutant	Protein	O75874 (Uniprot-TrEMBL)
IDH1 R132L mutant	Protein	O75874 (Uniprot-TrEMBL)
IDH1 R132S mutant	Protein	O75874 (Uniprot-TrEMBL)
IDH1 R132mutant dimers	Complex	R-HSA-880004 (Reactome)
NADP+	Metabolite	CHEBI:18009 (ChEBI)
NADPH	Metabolite	CHEBI:16474 (ChEBI)

Annotated Interactions

Source	Target	Type	Database reference	Comment
	2HG	Arrow	R-HSA-880053 (Reactome)
2OG			R-HSA-880053 (Reactome)
H+			R-HSA-880053 (Reactome)
IDH1 R132mutant dimers		mim-catalysis	R-HSA-880053 (Reactome)
	NADP+	Arrow	R-HSA-880053 (Reactome)
NADPH			R-HSA-880053 (Reactome)
			R-HSA-880053 (Reactome)	Mutant forms of IDH1 in which the arginine residue at position 132 has been replaced by histidine, cystine, leucine, or serine catalyze the reaction of 2-oxoglutarate and NADPH + H+ to form (R)-2-hydroxyglutarate and NADP+. Like normal IDH1, the mutant enzyme forms a dimer located in the cytosol (Dang et al. 2009). Such mutations occur frequently as a somatic event in human glioblastomas (Parsons et al. 2008). Cells expressing the mutant protein accumulate elevated levels of 2-hydroxyglutarate, probably in the cytosol as IDH1 is a cytosolic enzyme. The fate of the 2-hydroxyglutarate is unclear, but the high frequency with which the mutation is found in surveys of primary tumors is consistent with the possibility that it is advantageous to the tumor cells (Dang et al. 2009).